Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Blockade of bulky lymphoma‐associated CD55 expression by RNA interference overcomes resistance to complement‐dependent cytotoxicity with rituximab
Yasuhito Terui, Takuma Sakurai, Yuko Mishima, et al.
Cancer Science (2005) Vol. 97, Iss. 1, pp. 72-79
Open Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response
Rogier M. Thurlings, Koen Vos, C A Wijbrandts, et al.
Annals of the Rheumatic Diseases (2007) Vol. 67, Iss. 7, pp. 917-925
Open Access | Times Cited: 313
Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance
Junji Hiraga, Akihiro Tomita, Takumi Sugimoto, et al.
Blood (2009) Vol. 113, Iss. 20, pp. 4885-4893
Open Access | Times Cited: 248
The Role of Complement in Tumor Growth
Rubén Pı́o, Leticia Corrales, John D. Lambris
Advances in experimental medicine and biology (2013), pp. 229-262
Open Access | Times Cited: 191
Rituximab resistance
Andrew R. Rezvani, David G. Maloney
Best Practice & Research Clinical Haematology (2011) Vol. 24, Iss. 2, pp. 203-216
Open Access | Times Cited: 189
Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis
Koen Vos, Rogier M. Thurlings, Carla A. Wijbrandts, et al.
Arthritis & Rheumatism (2007) Vol. 56, Iss. 3, pp. 772-778
Closed Access | Times Cited: 180
The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy
Xuhui Zhou, Weiguo Hu, Xuebin Qin
The Oncologist (2008) Vol. 13, Iss. 9, pp. 954-966
Open Access | Times Cited: 174
Engineered therapeutic antibodies with improved effector functions
Tsuguo Kubota, Rinpei Niwa, Mitsuo Satoh, et al.
Cancer Science (2009) Vol. 100, Iss. 9, pp. 1566-1572
Open Access | Times Cited: 148
Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer
Saskia Meyer, Jeanette H.W. Leusen, Péter Boross
mAbs (2014) Vol. 6, Iss. 5, pp. 1133-1144
Open Access | Times Cited: 100
Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies
Ronald P. Taylor, Margaret A. Lindorfer
Seminars in Immunology (2016) Vol. 28, Iss. 3, pp. 309-316
Closed Access | Times Cited: 87
The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
Josée Golay, Ronald P. Taylor
Antibodies (2020) Vol. 9, Iss. 4, pp. 58-58
Open Access | Times Cited: 77
A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections
Narges Seyfizadeh, Nayer Seyfizadeh, Justin Hasenkamp, et al.
Critical Reviews in Oncology/Hematology (2015) Vol. 97, pp. 275-290
Closed Access | Times Cited: 79
Complement and cellular cytotoxicity in antibody therapy of cancer
Siao‐Yi Wang, George J. Weiner
Expert Opinion on Biological Therapy (2008) Vol. 8, Iss. 6, pp. 759-768
Closed Access | Times Cited: 88
Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development
Dana Gancz, Zvi Fishelson
Molecular Immunology (2009) Vol. 46, Iss. 14, pp. 2794-2800
Closed Access | Times Cited: 83
The dual role of complement in cancer and its implication in anti-tumor therapy
Ioannis Kourtzelis, Stavros Rafail
Annals of Translational Medicine (2016) Vol. 4, Iss. 14, pp. 265-265
Open Access | Times Cited: 48
Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma
Yasuhito Terui, Yuji Mishima, Natsuhiko Sugimura, et al.
Clinical Cancer Research (2009) Vol. 15, Iss. 7, pp. 2523-2530
Open Access | Times Cited: 68
Disease activity–guided rituximab therapy in rheumatoid arthritis: The effects of re‐treatment in initial nonresponders versus initial responders
Rogier M. Thurlings, Koen Vos, Daniëlle M. Gerlag, et al.
Arthritis & Rheumatism (2008) Vol. 58, Iss. 12, pp. 3657-3664
Closed Access | Times Cited: 66
Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack In Vitro
Nicolas A. Geis, S. Zell, R. Rutz, et al.
Current Cancer Drug Targets (2010) Vol. 10, Iss. 8, pp. 922-931
Closed Access | Times Cited: 64
Prognostic Significance of CD55 Expression in Breast Cancer
Jun‐ichiro Ikeda, Eiichi Morii, Yalan Liu, et al.
Clinical Cancer Research (2008) Vol. 14, Iss. 15, pp. 4780-4786
Closed Access | Times Cited: 61
Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance
Akihiro Tomita
Journal of Clinical and Experimental Hematopathology (2016) Vol. 56, Iss. 2, pp. 89-99
Open Access | Times Cited: 41
Mortalin inhibitors sensitize K562 leukemia cells to complement‐dependent cytotoxicity
David Pilzer, M. Saar, Keizo Koya, et al.
International Journal of Cancer (2009) Vol. 126, Iss. 6, pp. 1428-1435
Open Access | Times Cited: 54
Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: A retrospective study
Mei Liu, Yajun Yang, Hong Zheng, et al.
Oncology Reports (2014) Vol. 32, Iss. 6, pp. 2619-2627
Open Access | Times Cited: 39
Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials
Daniëlle M. Gerlag, Paul P. Tak
Best Practice & Research Clinical Rheumatology (2008) Vol. 22, Iss. 2, pp. 311-323
Closed Access | Times Cited: 49
Superior Activity of Fusion Protein scFvRit:sFasL over Cotreatment with Rituximab and Fas Agonists
Edwin Bremer, Bram ten Cate, Douwe F. Samplonius, et al.
Cancer Research (2008) Vol. 68, Iss. 2, pp. 597-604
Open Access | Times Cited: 48
Molecular mechanisms of the antitumor effects of anti-CD20 antibodies
Magdalena Winiarska
Frontiers in bioscience (2010) Vol. 16, Iss. 1, pp. 277-277
Open Access | Times Cited: 43
The development of targeted therapies in rheumatoid arthritis
Edward M Vital, Paul Emery
Journal of Autoimmunity (2008) Vol. 31, Iss. 3, pp. 219-227
Closed Access | Times Cited: 42
Page 1 - Next Page

Scroll to top